Patents Examined by Jeffrey S. Parkin
  • Patent number: 10660854
    Abstract: A platform enabling the manufacture of thermostable vaccines by incorporating recombinantly expressed, viral envelope proteins in their native conformation into ether glycerophospholipid nanodisc structures that simulate the natural environment of the envelope proteins. The ether glycerophospholipids include ether-linked hydrophobic side chains, and are derived from or modeled after those found in thermophile bacteria, which increase thermostability, thereby significantly enhancing the vaccine's potency, enabling the production of highly multivalent vaccines incorporating multiple variants of the viral antigen, and improving stability and shelf-life.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: May 26, 2020
    Assignee: Batavia Biosciences Inc.
    Inventors: David Foster, Menzo Jans Emco Havenga
  • Patent number: 10654943
    Abstract: Provided are tri-specific fusion antibodies created to target multiple epitopes of the Human Immunodeficiency Virus (HIV). The fusion antibodies provide improved potency and breadth against HIV as compared to monospecific and bispecific antibodies, and additionally provide a high barrier against viral resistance. Also disclosed are pharmaceutical formulations and therapeutic methods utilizing such fusion proteins.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: May 19, 2020
    Assignee: The Rockefeller University
    Inventors: David Ho, Jian Yu, Xin Yao, Yaoxing Huang
  • Patent number: 10655110
    Abstract: A highly safe dengue vaccine was invented that induced a neutralizing antibody response against all of the four serotypes of dengue virus without developing more than a fixed level of viremia with single administration. A tetravalent dengue virus formulation is provided that is excellent in both efficacy (neutralizing antibody response) and safety (viremia).
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: May 19, 2020
    Assignee: KM BIOLOGICS CO., LTD.
    Inventors: Kengo Sonoda, Yasuhiko Shinmura, Susumu Yamaori, Motoharu Abe, Shinichi Maruno, Shota Takagi, Yasuhisa Hayashi, Kazuhisa Kameyama, Fusae Komura, Aki Fukuda, Naomi Uchida, Masaya Yoshimura
  • Patent number: 10647748
    Abstract: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: May 12, 2020
    Assignee: The Scripps Research Institute
    Inventors: Leopold Kong, Ian A. Wilson, Natalia De Val, Andrew B. Ward, Dennis Burton, Linling He, Jiang Zhu
  • Patent number: 10647754
    Abstract: The invention provides a polypeptide comprising a single domain CD4, as well as a fusion protein comprising the single domain CD4 and one or more fusion partners. A nucleic acid encoding the polypeptide or fusion protein, as well as compositions or cells comprising the polypeptide, fusion protein, or nucleic acid also are provided.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: May 12, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Weizao Chen, Prabakaran Ponraj
  • Patent number: 10640549
    Abstract: This disclosure is directed to compositions and methods for utilizing the boundaries of the C-terminal domains of Nucleoprotein from Zaire Ebola virus as highly stable recombinant protein antigens to generate antibodies for diagnosis and treatment of Ebola virus infection.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: May 5, 2020
    Assignees: University of Virginia Patent Foundation, The University of Chicago
    Inventors: Zygmunt S. Derewenda, Daniel A. Engel, Anthony Kossiakoff, Elena K. Davydova, Mateusz Jaskolowski
  • Patent number: 10617645
    Abstract: Instead of generating immune responses to several HIV proteins and risk over activating more CD4+ T cells (easy targets for HIV-1 infection) as current candidate vaccines try to do, a lower magnitude, narrowly focused, well maintained virus specific CD8+ T cell response to multiple subtypes should destroy and eliminate a few founder viruses without inducing inflammatory responses that may activate more CD4+ T cells and provide more targets for HIV-1 virus infection. Specifically, described herein is a method that focuses the immune response to the 12 protease cleavage sites.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: April 14, 2020
    Inventor: Ma Luo
  • Patent number: 10611827
    Abstract: The disclosure provides non-human primate-derived binding molecules, e.g., antibodies or antigen-binding fragments thereof, that can bind to orthologous epitopes found on two or more filovirus species or strains.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: April 7, 2020
    Assignees: INTEGRATED BIOTHERAPEUTICS, INC., THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Mohammad Javad Aman, Frederick Wayne Holtsberg, Sven G. Enterlein, Katie A. Howell, Zhen-Yong Keck, Steven K. H. Foung
  • Patent number: 10605808
    Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is a common human, human-like, or humanized light chain. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: March 31, 2020
    Assignee: Merus N.V.
    Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. Dekruif, Erwin Houtzager
  • Patent number: 10590187
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: March 17, 2020
    Assignees: California Institute of Technology, The Rockefeller University
    Inventors: Ron Diskin, Pamela J. Bjorkman, Michel C. Nussenzweig, Johannes Scheid
  • Patent number: 10588960
    Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: March 17, 2020
    Assignee: DUKE UNIVERSITY
    Inventors: Barton F. Haynes, S. Munir Alam, Hua-Xin Liao
  • Patent number: 10584355
    Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: March 10, 2020
    Assignees: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Nancy J. Sullivan, Gary J Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
  • Patent number: 10576141
    Abstract: The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against filovirus infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA and FPV vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a Marburg virus (MARV) or Ebola virus glycoprotein. Specifically, the invention relates to recombinant MVA comprising Ebola virus glycoprotein and virion protein 40. The invention also relates to products, methods and uses thereof as well as prime/boost regimens of MVA and genetically engineered (recombinant) FPV, e.g., suitable to induce a protective immune response in a subject.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: March 3, 2020
    Assignee: Bavarian Nordic A/S
    Inventors: Ariane Volkmann, Robin Steigerwald, Hubertus Hochrein, Ulrike Dirmeier, Henning Lauterbach, J├╝rgen Hausmann Hausmann
  • Patent number: 10562969
    Abstract: This invention relates to the use of antibody therapy as a treatment substitute, or for treatment interruption, to treat HIV-1 infected patients. Specifically, the present invention relates to the use of antibody therapy, such as PRO 140 monoclonal anti-body therapy, as a monotherapy for treatment of HIV-1 infected patients.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: February 18, 2020
    Assignee: Cytodyn Inc.
    Inventors: Robert T. Schooley, Nader Z. Pourhassen
  • Patent number: 10550441
    Abstract: The invention provides a method for determining whether a human immunodeficiency virus is resistance to a viral entry inhibitor. The methods are particularly useful for determining resistance to inhibitors that act by a non-competitive mechanism. In certain aspects, the methods comprise determining whether an HIV population is resistant to an HIV entry inhibitor, comprising determining a log-sigmoid inhibition curve comprising data points for entry of the HIV population in the presence of varying concentrations of the HIV entry inhibitor, wherein if the entry of the HIV population cannot be completely inhibited by the HIV entry inhibitor, the HIV population is resistant to the HIV entry inhibitor.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: February 4, 2020
    Assignee: Monogram BioSciences, Inc.
    Inventor: Christos J. Petropoulos
  • Patent number: 10545149
    Abstract: A method for detecting HIV infection in a mammal is disclosed. The method contains the steps of isolating exosomes from a urine sample of a mammal and detecting the presence of HIV-specific biomarker in said isolated exosomes. A method for diagnosing a mammal with an HIV-associated disease, in particular, HIV-associated nephropathy is also disclosed.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: January 28, 2020
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Gale W. Newman, Mike Powell, Akins Doherty, Chamberlain Obialo, Claudette Mitchell-Ali, Khalid Bashir, Mafuz Khan
  • Patent number: 10519222
    Abstract: The present invention relates anti-HIV therapies and prophylaxis. Specifically, the invention relates to broadly neutralizing antibodies against HIV-1, nucleic acids encoding these antibodies, vectors comprising the nucleic acids and cells and pharmaceutical compositions Comprising said vectors and/or antibodies. The present invention also relates to use of the antibodies and/or vectors for the treatment and/or prevention of HIV-1 infection in a subject. Furthermore, the invention also relates to a kit containing the antibodies of the invention.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: December 31, 2019
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, CENTRE FOR THE AIDS PROGRAMME OF RESEARCH IN SOUTH AFRICA, UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG, NATIONAL HEALTH LABORATORY SERVICE
    Inventors: Chaim Aryeh Schramm, Jason Gorman, John Mascola, Lawrence Stewart Shapiro, Lynn Morris, Nicole Amy Doria-Rose, Penelope Linda Moore, Peter Dak Pin Kwong, Salim Safurdeen Abdool Karim
  • Patent number: 10500274
    Abstract: This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load reducing dose achieves an average maximum decrease of viral load in the subject of at least 1.83 log10 to 2.5 log10 at about ten days following administration of the CCR5 receptor antagonist and wherein the viral load reducing dose further achieves a mean viral load reduction of 1.7 log10 at about nine days following administration of the CCR5 receptor antagonist.
    Type: Grant
    Filed: September 17, 2012
    Date of Patent: December 10, 2019
    Assignee: CytoDyn Inc.
    Inventors: William C. Olson, Paul J. Maddon, Daniel C. Pevear, Robert J. Israel, Jose D. Murga
  • Patent number: 10501499
    Abstract: The present invention relates to novel peptides and methods for treatment, diagnosis and prognosis of virus infections including infections with HCV, HIV, HPV, CMV and Influenza. The invention further relates to methods for identifying and providing peptides useful for the treatment and diagnosis.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: December 10, 2019
    Assignee: BIONOR IMMUNO AS
    Inventors: Birger Sorensen, Mats Okvist, Arnt Ove Hovden, Maja Sommerfelt Gronvold
  • Patent number: 10500264
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: December 10, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai